1
Clinical Trials associated with anti-tumor intestinal bacteria(Sun Yat-sen University)Safety and Efficacy of Bacterial Strain RX-af01 Combined With PD-1 Antibody in Patients With Refractory Advanced Solid Tumors
This phase I trial evaluates the effects of RX-af01 in combination with toripalimab (PD-1 antibody), in treating patients with refractory advanced solid tumors, including melanoma, nasopharyngeal squamous carcinoma, esophageal squamous cell carcinoma, gastric adenocarcinoma, renal cell carcinoma, et al. RX-af01 is a kind of anti-tumor intestinal bacteria developed by our research group. Its main components are symbiotic bacteria from human intestine - Alisipes finegoldii (A. finegoldii.), which is a Gram negative anaerobic bacteria. Our previous research shows that A finegoldii. can significantly enhance the anti-tumor activity of PD-1 antibody in multiple mouse tumor models. Mechanism research shows that A finegoldii. can increase the infiltration of CD4 and CD8 positive immune cells in the tumor microenvironment, and enhances the anti-tumor activity of immune cells. The primary aim of this study is to explore the efficacy and safety of RX-af01 combined with PD-1 antibody in refractory advanced solid tumors.
100 Clinical Results associated with anti-tumor intestinal bacteria(Sun Yat-sen University)
100 Translational Medicine associated with anti-tumor intestinal bacteria(Sun Yat-sen University)
100 Patents (Medical) associated with anti-tumor intestinal bacteria(Sun Yat-sen University)
100 Deals associated with anti-tumor intestinal bacteria(Sun Yat-sen University)